TORONTO and CHICAGO, June 24, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced a partnership with the…


Previous articleCybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
Next articleField Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results